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Abstract
Objective: Parkinson’s	disease	psychosis	(PDP)	is	a	frequent	complication	of	idiopathic	
Parkinson’s	disease	(iPD)	with	significant	impact	on	quality	of	life	and	association	with	
poorer	outcomes.	Atypical	antipsychotic	drugs	(APDs)	are	often	used	for	the	treatment	
of	PDP;	however,	their	use	is	often	complicated	by	adverse	drug	reactions	(ADRs).	In	
this	study,	we	present	patients	with	PDP	who	were	treated	with	the	most	commonly	
used	atypical	antipsychotic	agents	and	review	their	respective	ADRs.
Methods: A	retrospective	study	was	carried	out	to	include	a	total	of	45	patients	with	
iPD	who	visited	a	movement	disorders	clinic	between	2006	and	2015.	All	PDP	patients	
treated	with	atypical	APDs	were	included	in	the	analysis	for	their	specific	ADRs.
Results: Forty-	five	iPD	patients	(mean	age	of	onset:	62.67	±	9.86	years)	were	included,	
of	those	10	patients	had	psychosis	(mean	age	of	onset:	76.80	±	4.61	years).	Of	the	45	
patients,	 22.2%	 were	 found	 to	 have	 psychotic	 symptoms,	 of	 whom	 70%	 had	
hallucinations,	20%	had	delusions,	 and	10%	 illusions.	 Seventy	percent	of	psychotic	
symptoms	occurred	after	ten	or	more	years	from	diagnosis	of	iPD.	PDP	patients	were	
treated	with	quetiapine,	olanzapine,	and	risperidone	separately	or	in	combination,	all	
of	which	were	found	to	have	certain	ADRs.
Limitations: This	study	was	limited	by	its	retrospective	study	design	and	small	sample	
size	and	with	likely	selection	bias.
Conclusions: The	prevalence	of	PDP	is	relatively	high	in	older	patients	with	iPD.	The	
uses	 of	 the	 currently	 available	 atypical	 APDs	 in	 this	 patient	 population	 are	 often	
complicated	by	ADRs.	The	selective	5-	HT2A	inverse	agonist,	pimavanserin,	could	be	a	
better	alternative	in	the	treatment	of	PDP.
K E Y W O R D S
adverse	drug	reactions,	antipsychotics,	Parkinson’s	disease,	Parkinson’s	disease	psychosis
1  | INTRODUCTION
Parkinson’s	 disease	 (PD)	 is	 a	 slowly	 progressive	 neurodegener-
ative	 disease	 that	 affects	 7–10	 million	 people	 worldwide	 and	
is	 more	 common	 in	 older	 people.	 The	 number	 of	 PD	 patients	 is	
expected	 to	 increase	 in	 parallel	 to	 the	 rising	 age	 of	 our	 popula-
tion.	 PD	 is	 characterized	 by	 a	 progressive	 loss	 of	motor	 function	
and	 a	 wide	 spectrum	 of	 nonmotor	 symptoms	 (NMSs).	 NMSs	 in	
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PD	 have	 been	 systematically	 described	 and	 include	 a	 high	 prev-
alence	 of	 neuropsychiatric	 symptoms,	 such	 as	 psychosis,	 depres-
sion,	 cognitive	 	impairment,	 and	 sleep	 disturbances	 (Munhoz,	
Moro,	Silveira-	Moriyama,	 &	 Teive,	2015).	 Psychosis	 in	 PD,	 also	
known	as	Parkinson’s	disease	psychosis	(PDP),	can	affect	more	than	
50%	of	people	with	PD	and	result	in	a	significant	impact	on	patients’	
quality	of	life	(Starkstein,	Brockman,	&	Hayhow,	2012).	In	addition,	
symptoms	of	PDP	are	associated	with	increased	caregiver	burden,	
greater	 likelihood	 of	 placement	 in	 nursing	 homes	 and	 increased	
mortality.
PDP	 is	 characterized	by	hallucinations	 (particularly	visual),	 delu-
sions,	 illusions	 and	 false	 sense	 of	 presence.	The	 etiology	 of	 PDP	 is	
thought	 to	 be	multifactorial.	 Some	 studies	 show	 that	 the	 develop-
ment	of	PDP	is	associated	with	the	use	of	dopaminergic	medications	
(Bizzarri	 et	al.,	 2015).	 However,	 other	 studies	 suggest	 medications	
alone	cannot	explain	emergence	of	psychosis	(including	no	dose	rela-
tionship	 and	 present	 in	 newly	 diagnosed	 patients	 (Pagonabarraga	
et	al.,	2016).	There	are	also	some	studies	suggest	that	increased	age,	
male	gender,	lower	levels	of	education,	older	age	at	onset,	longer	dis-
ease	duration	and	serious	medical	conditions	also	contribute	to	the	
development	 of	PDP	 (Gama	et	al.,	 2015;	Zhu,	van	Hilten,	 Putter,	&	
Marinus,	2013).
What	is	also	noteworthy	is	that	the	pathophysiology	of	PDP	is	
most	 likely	 attributed	 to	 disorders	 of	 the	 cholinergic	 and	 seroto-
nergic	systems	(Mocci	et	al.,	2014;	Rolland	et	al.,	2014)	as	well	as	
to	changes	 in	brain	structure	 (Kiferle	et	al.,	2014).	With	 regard	 to	
therapeutics,	PDP	can	be	difficult	to	treat	due	to	the	 lack	of	safe,	
effective	pharmacological	treatments.	The	first-	line	strategy	in	the	
treatment	 of	 persistent	 and	 problematic	 PDP	 is	 represented	 by	
reduction	 in	 anti-	PD	 medications.	 However	 due	 to	 different	 and	
multiple	 factors	 and	 unclear	 pathophysiology,	 it	 does	 not	 always	
work	well.	Besides,	reducing	anti-	PD	medications	may	aggravate	PD	
symptoms.	Antipsychotics	are	usually	prescribed	off-	label	(Goldman	
&	Holden,	2014;	Seppi	et	al.,	2011).	Compared	with	first-	generation	
antipsychotics	 or	 typical	 antipsychotics,	 second-	generation	 anti-
psychotics	(SGAs)	produce	fewer	adverse	effects	on	motor	function	
and	serum	prolactin	elevation,	presumably	due	 to	dual	 serotonin-	
dopamine	antagonism	(Noel,	2007).	As	a	result,	SGAs,	also	known	
as	atypical	antipsychotic	drugs	(APDs)	are	frequently	prescribed	for	
patients	with	PDP.
The	 search	 for	 effective	 strategies	 for	 the	 treatment	 of	
PDP	has	been	 an	 area	 of	 much	 interest.	 The	 only	 drug	 with	
	confirmed	 benefit	 without	 worsening	 Parkinsonism	 has	
been	clozapine	 (Seppi	et	al.,	 2011).	 However	 the	 avoidance	
of	 clozapine	 in	 large	 part	 due	 to	 the	 inconvenience	 of	 frequent	
blood	 testing	 (Hack	 et	al.,	 2014).	 Additionally,	 patients	 and	 pro-
viders	must	both	be	 registered	with	 the	FDA	 for	clozapine	 to	be	
prescribed.	 For	 these	 reasons,	APDs	 such	 as	 quetiapine,	 risperi-
done,	and	olanzapine	are	more	commonly	used.	In	this	article,	we	
review	patients	with	PDP	who	were	treated	with	these	three	atyp-
ical	antipsychotic	drugs	separately	or	in	combination	over	the	past	
10	years	 in	 an	 outpatient	 specialty	 clinic	 and	 their	 adverse	 drug	
reactions	(ADRs).
2  | MATERIAL AND METHODS
A	retrospective	chart	review	of	electronic	medical	records	(EMRs)	was	
performed	on	445	patients	who	visited	our	movement	disorders	clinic	
at	UC	Davis	Medical	Center	between	 January	2006	and	December	
2015.	 Because	 data	 were	 collected	 retrospectively	 from	 records	
and	the	identity	of	patients	was	not	obtained,	informed	consent	was	
not	 required.	After	 reviewing	each	patient’s	 EMR,	 all	 patients	were	
screened	for	a	diagnosis	of	 iPD	with	supportive	features	on	a	com-
plete	 neurological	 examination	 including	muscle	 tone,	 posture,	 gait	
and	 involuntary	 movement.	 Besides,	 iPD	 patients	 with	 incomplete	
records	and/	or	with	psychotic	symptoms	attributable	to	other	condi-
tions	were	excluded.	Demographic	variables	 collected	 included	 sex,	
age	range,	and	age	at	onset	of	PD	and	age	at	onset	of	PDP.	Clinical	
variables	include	antiparkinsonian	treatment,	APD	use	and	ADRs,	and	
symptoms	 consistent	with	 psychosis.	 On	 the	 basis	 of	 our	 systemic	
chart	review,	we	were	able	to	confirm	the	diagnosis	of	iPD	in	45	of	
445	patients,	using	the	United	Kingdom	Parkinson’s	Disease	Society	
Brain	Bank	(UKPDSBB)	diagnostic	criteria.	Ten	of	45	patients	with	iPD	
were	included	in	this	report	that	met	the	diagnostic	criteria	for	psy-
chosis	in	Parkinson’s	disease	published	in	2007	and	updated	in	2013.
Data	were	 reported	 as	 simple	 statistics,	 including	 number,	 per-
centage,	mean,	 and	 standard	 deviation.	We	 used	 constituent	 ratios	
(CR)	to	evaluate	different	psychotic	symptoms	 in	patients	with	PDP.	
SPSS	13.0	was	used	to	compute	the	mean	and	standard	deviation.
3  | RESULTS
Demographic	and	clinical	characteristics	of	iPD	patients	are	shown	in	
Table	1.	Forty-	five	iPD	patients	(mean	age	of	onset:	62.67	±	9.86	years)	
were	included;	of	those,	10	patients	(22.2%)	had	symptoms	of	psycho-
sis	(mean	age	of	onset:	76.80	±	4.61	years).	The	psychotic	symptoms	
included	hallucinations	(70%),	delusions	(20%),	and	illusions	(10%).	All	
TABLE  1 Demographic	and	clinical	characteristics	of	iPD	patients
Measurement Mean ± SD or %
Age	(years) 75.87	±	10.01
Males	(%) 28/45	(62.2)
Age	at	onset	of	PD	(years) 62.67	±	9.86
Age	at	onset	of	PDP	(years) 76.80	±	4.61
L-	dopa	monotherapy,	n	(%) 21	(46.7)
L-	dopa	+	agonist,	n	(%) 14	(31.1)
Agonist	monotherapy,	n	(%) 4	(8.9)
Other	type	of	antiparikinson	drugs 6	(15.3%)
PDP,	n	(%) 10/45	(22.2)
Hallucinations,	n	(%) 7/10	(70)
Delusions,	n	(%) 2/10	(20)
Illusion,	n	(%) 1/10	(10)
iPD,	idopathic	Parkinson’s	disease;	PDP,	Parkinson’s	disease	psychosis;	SD,	
standard	deviation.
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hallucination	 reported	among	our	cohort	were	visual	hallucinations.	
Descriptions	of	visual	hallucinations	 included	seeing	people	and	fire	
or	 dots	 of	 light	 in	 the	 peripheral	 fields.	 Additionally,	 two	 patients	
reported	paranoid	delusions.	One	of	them	thought	that	people	were	
planning	on	harming	him	while	the	other	patient	thought	that	her	hus-
band	was	having	an	extramarital	affair.	The	patient	who	experienced	
an	illusion	noted	that	the	table	appeared	to	move	like	a	dog.	Psychotic	
symptoms	 occurred	 up	 to	 several	 times	 per	 day	 and	 mostly	 while	
alone,	or	in	a	quiet	environment.
In	our	 report,	 there	were	46.7%	 iPD	patients	exposed	 to	L-	dopa	
monotherapy	and	23.8%	of	these	patients	were	reported	to	develop	
PDP.	Of	those	taking	L-	dopa	and	dopamine	agonist	therapy	together,	
28.6%	developed	 psychosis.	Twenty-	five	 percent	 reported	 onset	 of	
psychosis	 during	 dopamine	 agonist	 therapy	 alone	(Table	2).	None	 of	
the	six	patients	on	nondopaminergic	drugs	for	PD	developed	psychosis.
Psychotic	 symptoms	 mainly	 occurred	 ten	 or	 more	 years	 after	
the	diagnosis	of	 iPD.	Psychotic	symptoms	were	observed	 in	10%	of	
patients	 within	 5	years	 of	 diagnosis	 and	 in	 80%	 of	 patients	 within	
15	years	 of	 diagnosis.	 One-	half	 occurred	 in	 the	 interval	 of	 10	 to	
15	years	after	the	diagnosis	of	iPD	(Table	3).	We	also	found	that	the	
male	patients	with	iPD	constituted	60%	of	incident	psychosis	cases,	
with	a	male	to	female	ratio	of	3:2	(Table	3).
The	ten	PDP	patients	we	reviewed	were	treated	with	quetiapine,	
olanzapine	 and/or	 risperidone	 separately	 or	 in	 combination.	 Six	
patients	reported	mild	 improvement	of	psychosis	when	treated	with	
quetiapine,	whereas	one	patient	had	no	benefit	from	it.	Two	patients	
received	olanzapine	monotherapy	and	both	had	improvement	in	psy-
chotic	 symptoms.	 Two	 patients	were	 treated	with	 risperidone:	 one	
received	 risperidone	 monotherapy,	 whereas	 the	 other	 patient	 was	
treated	 with	 quetiapine	 initially,	 and	 then	 switched	 to	 risperidone.	
Both	 experienced	 alleviation	 of	 psychotic	 symptoms.	 However,	 all	
atypical	APDs	used	were	associated	with	ADRs	 (Table	4).	Both	que-
tiapine	 and	 olanzapine	 could	 cause	 sedation	 and	 sialorrhea;	 both	
olanzapine	and	risperidone	resulted	in	worsening	of	motor	symptoms.	
The	daily	dose	range	of	quetiapine,	olanzapine,	and	risperidone	was	
25	mg/day–150	mg/day,	 2.5	mg/day–5	mg/day,	 and	 1	mg/day,	
respectively	(Table	4).
4  | DISCUSSION
With	 a	 shift	 in	 our	 understanding	 of	 Parkinson’s	 disease	 over	 the	
past	two	decades,	we	have	developed	a	greater	appreciation	for	the	
NMS	 associated	with	 iPD	 including	 significant	 psychotic	 symptoms	
such	as	hallucinations.	Various	clinical	features	of	hallucinations	have	
been	described	with	a	prevalence	that	varies	widely	from	17	to	72%	
amongst	PDP	patients	(Meral	et	al.,	2007).	Consistent	with	previous	
studies,	our	current	report	also	found	that	visual	hallucinations	are	the	
most	 commonly	 reported	 psychotic	 symptom	 among	 PDP	 patients	
with	a	prevalence	of	70%	among	our	cohort.
In	our	study,	these	psychotic	symptoms	were	observed	in	70%	of	
patients	between	5	to	15	years	after	receiving	a	clinical	diagnosis	of	
PD,	with	one-	half	 occurring	10	 to	15	years	post	diagnosis.	We	also	
found	that	60%	of	PDP	patients	were	males,	but	with	a	similar	 inci-
dence	of	psychotic	symptoms	to	females,	considering	that	62.2%	of	
our	PD	patients	are	male.	While	a	recent	study	has	shown	that	older	
age	at	onset	and	female	sex	were	associated	with	an	increased	risk	of	
hallucinations	 through	cross-	sectional	 analyses	of	baseline	data	and	
longitudinal	 analyses	 of	 follow-	up	 data	 (Fernandez,	 Lapane,	 Ott,	 &	
Friedman,	2000),	 there	 is	no	consensus	whether	men	or	women	are	
more	likely	to	suffer	from	PDP.	After	all,	our	samples	are	small.
Important	 risk	 factors	 associated	with	 the	 development	 of	 psy-
chotic	 symptoms	 in	 iPD	are	older	 age,	 sex,	 longer	disease	duration,	
and	severity.	Additionally,	previous	studies	have	identified	that	dopa-
minergic	 medication	 treatment	 is	 associated	 with	 increased	 risk	 of	
developing	hallucinations	(Fénelon	&	Alves,	2010;	Reichmann,	2016),	
whereas	some	earlier	studies	have	questioned	the	causative	relation-
ship	of	dopaminergic	medications	with	PDP.	Through	our	small	sample	
Antiparkinsonian drugs Number of iPD Number of PDP Percentage (%)
L-	dopa	monotherapy 21 5 23.8
L-	dopa	+	Dopamine	agonist 14 4 28.5
Dopamine	agonist	
monotherapy
4 1 25
Other	type	of	antiparikinson	
drugs
6 0 0
iPD,	idopathic	Parkinson’s	disease;	PDP,	Parkinson’	s	disease	psychosis.
TABLE  2 The	percentage	of	iPD	
patients	developed	PDP	after	taking	
antiparkinsonian	drugs
Sex
Years
Total, n (%)<5 [5–10] [10–15] >15
Male	(n) 1 2 3 0 6	(60)
Female	(n) 0 0 2 2 4	(40)
Total,	n	(%) 1	(10) 2	(20) 5	(50) 2	(20) 10	(100)
iPD,	idopathic	Parkinson’s	disease;	PDP,	Parkinson’s	disease	psychosis.
TABLE  3 Onset	of	PDP	since	diagnosis	
of	iPD	(in	years)
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study,	we	 observed	 that	 the	 combination	 of	L-	dopa	with	 dopamine	
agonists	may	 contribute	 to	 the	 development	 of	 PDP	most	 strongly	
followed	by	L-	dopa	therapy	alone.	This	supports	a	possible	causal	rela-
tionship	between	dopaminergic	 replacement	 therapy	and	the	devel-
opment	of	hallucinations.
Given	 the	 high	 prevalence	 of	 PDP	 and	 its	 impact	 on	 quality	 of	
life,	there	has	been	significant	interest	in	optimizing	symptom	control	
through	the	use	of	available	atypical	APDs	despite	an	unclear	patho-
physiology	underlying	PDP.	Approved	in	1985,	clozapine	was	the	first	
atypical	 antipsychotic	 for	PDP,	with	findings	 to	 support	 therapeutic	
benefit	 without	 worsening	 of	 motor	 function.	 Despite	 its	 demon-
strated	 efficacy,	 subsequent	 studies	 have	 shown	 that	 clozapine	 has	
potentially	 fatal	 agranulocytosis	 (requiring	 frequent	 blood	 testing)	
and	myocarditis,	 in	 addition	 to	 relatively	milder	 side	 effects	 includ-
ing	 sedation,	 seizures,	 sialorrhea,	weight	gain,	 and	metabolic	distur-
bances	(Hack	et	al.,	2014;	Thomas	&	Friedman,	2010).	In	addition,	one	
recent	case	report	 in	an	elderly	woman	with	PDP	showed	clozapine	
may	induce	fatal	neuroleptic	malignant	syndrome	(NMS)	(Mesquita	&	
Siva,	2014).	Moreover,	frequent	pharmacy	visits	 is	another	 limit	fac-
tor.	Because	of	these	substantial	side	effects	with	clozapine	therapy,	it	
is	often	avoided	by	clinicians.	By	comparison,	quetiapine,	olanzapine,	
and	risperidone	are	proportionally	more	commonly	used.
Quetiapine,	 another	 first-	line	 treatment	 for	 PDP,	 is	 similar	 to	
clozapine	 in	 chemical	 structure.	Quetiapine	 does	 not	 require	moni-
toring	for	blood	dyscrasias	and	has	less	impact	on	motor	symptoms.	
Because	of	no	aggravation	of	motor	symptoms	and	relatively	easy	to	
use,	it	is	currently	considered	the	most	frequently	used	antipsychotic	
drug	in	PD	patients.	Nevertheless,	patients	with	PDP	who	are	exposed	
to	quetiapine	may	develop	certain	adverse	reactions,	such	as	sedation,	
orthostatic	hypotension,	dizziness,	headache,	 tachycardia,	hypersex-
uality,	constipation,	 rash,	and	even	neuroleptic	malignant	syndrome.	
Besides,	 there	 is	 insufficient	evidence	for	the	efficacy	of	quetiapine.	
Several	randomized	clinical	trials	demonstrated	no	change	in	psychotic	
outcomes	 with	 quetiapine	 (Lertxundi	 et	al.,	 2015;	 Prohorov,	 Klein,	
Miniovitz,	Dobronevsky,	&	Rabey,	2006).	In	our	current	report,	there	
were	 seven	PDP	patients	 treated	with	quetiapine,	 six	of	whom	had	
mild	improvement	of	their	psychosis,	and	one	had	no	benefit.	This	sug-
gests	that,	to	some	extent	quetiapine	improves	the	psychotic	symp-
toms	associated	with	iPD	(Rabey,	Prokhorov,	Miniovitz,	Dobronevsky,	
&	Klein,	2007).	Except	for	sedation	and	sialorrhea,	there	were	no	other	
adverse	drug	reactions	reported	with	quetiapine	in	our	cohort.
Two	 additional	 atypical	 APDs	 used	 in	 PDP	 are	 olanzapine	 and	
risperidone.	Most	 studies	 reported	 olanzapine	 can	 lead	 to	 intolera-
ble	motor	deterioration	even	at	 low	doses	 (Fernandez,	Trieschmann,	
&	 Friedman,	 2003).	Our	 findings	 are	 consistent	with	 these	 findings	
from	previous	studies.	Moreover,	 it	 is	remarkable	that	an	analysis	of	
the	 Spanish	 Pharmacovigilance	 Database	 indicated	 olanzapine	 also	
could	produce	NMS	in	PDP	patients;	likewise,	risperidone	can	dramat-
ically	aggravate	motor	function	in	some	PD	patients	(Lertxundi	et	al.,	
2015).	 Consequently,	 the	 American	 Academy	 of	 Neurology	 (AAN)	
does	not	recommend	these	two	drugs	for	the	treatment	of	PDP.	In	our	
study,	 four	 in	 ten	patients	who	received	olanzapine	and	 risperidone	
had	improvement	in	psychotic	symptoms,	but	both	drugs	resulted	in	
worsening	of	motor	symptoms.	Therefore	olanzapine	and	risperidone	
should	be	generally	avoided	by	movement	disorders	clinicians.
Nonetheless,	our	findings	must	be	interpreted	in	light	of	the	inher-
ent	limitations	of	this	study.
The	 study	was	 retrospective	with	 a	 small	 sample	 size	 and	with	
likely	selection	bias.	Because	of	this	limitation,	it	is	hard	to	draw	firm	
conclusions	with	regard	to	causation/risk	factors.	A	larger	sample	size	
would	be	needed	to	provide	more	robust	conclusions.
4.1 | New treatment options
PDP	 remains	 a	 significant	 therapeutic	 challenge.	 The	 therapeutic	
options	 currently	 in	 use,	 as	 described	 above,	 act	 as	 antagonists	 on	
mesolimbic	dopamine	receptors,	but	also	have	secondary	pharmaco-
logical	effects	of	blocking	dopamine	(DA)	D2	receptors,	and	thereby	
interfere	with	the	effect	of	dopamine	replacement	therapy	on	motor	
function.	 In	 addition,	 all	 the	 medications	 mentioned	 in	 our	 manu-
script	for	treatment	of	PDP	symptoms	have	a	boxed	warning	about	
increased	risk	of	death	in	elderly	people	with	dementia.	Those	pose	
significant	clinical	challenges.	A	post	hoc	analysis	from	a	multicenter,	
open-	label	extension	study	showed	that	current	antipsychotic	medi-
cations	significantly	increased	the	mortality	rate	and	adverse	events	in	
people	with	PDP	(Weintraub	et	al.,	2016).	To	date,	there	has	not	been	
an	agent	that	can	reliably	 improve	the	psychotic	symptoms	without	
having	adverse	side	effects	such	as	worsening	the	motor	symptoms	of	
PD,	or	sedation.	In	light	of	this	dilemma,	researchers	have	looked	to	a	
novel	selective	5-	HT2A	and	5-	HT2c	with	40	fold	less	affinity	receptor	
inverse	 agonist	 agent,	 ACP-	103,	 without	 dopaminergic,	 adrenergic,	
histaminergic,	or	muscarinic	affinity.	This	agent	has	been	confirmed	
as	a	potent,	efficacious,	orally	active	5-	HT2A	receptor	inverse	agonist	
with	a	behavioral	and	pharmacological	profile	consistent	with	utility	as	
an	antipsychotic	agent	(Vanover	et	al.,	2006).
The	 behavioral	 effects	 of	 pimavanserin	 (formerly	 ACP-	103)	 are	
similar	 to	 those	 of	 atypical	 APDs	 like	 quetiapine,	 olanzapine	 and	
risperidone,	which	have	appreciable	antagonist	activities	at	5-	HT2A	
receptors.	 However,	 unlike	 the	 atypical	 APDs,	 pimavanserin	 lacks	
DA	D2	antagonist	activity	and	thus	does	not	have	the	same	delete-
rious	effect	on	dopamine	replacement	therapy	and	does	not	worsen	
motor	 symptoms	 (Shotbolt	 et	al.,	 2009).	Moreover,	 it	 is	 particularly	
TABLE  4 Adverse	drug	reactions	of	different	antipsychotics
Drug
Number of 
patients taking 
atypical APDs
Dosage 
(mg/day) ADRs
Quetiapine 7 25–150 Sedation,	
sialorrhea
Olanzapine 2 2.5–5 Motor	worsening,	
sedation,	
sialorrhea
Risperidone 2 1 Motor	worsening
iPD,	idopathic	Parkinson’s	disease;	PDP,	Parkinson’s	disease	psychosis;	SD,	
standard	 deviation;	 ADRs,	 adverse	 drug	 reactions;	 APDs,	 Antipsychotic	
drugs.
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interesting	 to	 note	 that	 pimavanserin	 has	 some	 unique	 pharmaco-
logical	 properties	 compared	 with	 the	 first-	 and	 second-	generation	
antipsychotics.	Pimavanserin	not	only	reduces	5HT2	receptor	activity	
even	below	baseline	levels,	without	acting	on	other	receptors,	but	can	
also	induce	a	pharmacological	response	opposite	to	that	of	an	agonist,	
thus	named	as	a	“selective	inverse	agonist”.
An	 animal	 model	 of	 PD	 showed	 that	 pimavanserin	 not	 only	
reversed	the	psychotic	behaviors,	but	did	so	without	worsening	motor	
function	or	blocking	 the	ability	of	 L-	Dopa	 to	 improve	motor	behav-
ior	 (McFarland,	Price,	&	Bonhaus,	2011).	They	also	found	that	pima-
vanserin	had	a	higher	therapeutic	ratio	than	quetiapine	or	clozapine	
(Hubbard,	Hacksell,	&	McFarland,	2013).	Several	studies	have	demon-
strated	the	clinical	benefit	of	pimavanserin	in	PDP.	A	double	blind	ran-
domized	multi-	center	dose-	escalation	phase	2	study	in	PDP	patients	
indicated	better	safety	and	tolerability	of	pimavanserin.	It	also	demon-
strated	the	ability	to	 improve	PDP	without	worsening	Parkinsonism,	
causing	 sedation,	 agranulocytosis	 or	 NMS	 (Meltzer	 et	al.,	 2010).	
Subsequently,	a	randomized,	placebo-	controlled	phase	3	trial	further	
supported	that	pimavanserin	benefit	patients	with	PDP	for	whom	few	
other	treatment	options	exist	(Cummings	et	al.,	2014),	which	was	piv-
otal	study	that	led	to	its	FDA	approval.	These	studies	reported	ADRs	
of	nausea,	vomiting	and	a	small	QT	interval	 increase	without	associ-
ated	adverse	cardiac	events.	These	ADRs	were	considered	to	be	dose-	
limiting	and	less	serious.
Several	questions	regarding	the	treatment	of	psychotic	symptoms	
in	iPD	remain.	As	a	novel	selective	5-	HT2A	inverse	agonist,	pimavan-
serin	may	 complement	 or	 even	 replace	 current	 available	 treatment.	
NUPLAZID™	(pimavanserin)	has	been	approved	by	the	U.S.	Food	and	
Drug	Administration	on	April	29,	2016.	However,	 it	will	 still	 require	
considerable	postmarketing	research	and	investigation	to	ensure	the	
sustained	safety	and	efficacy	of	pimavanserin.
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